NCT00124527View on ClinicalTrials.gov

Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
Thyroid Cancer
Interventions
DRUG

Irofulven + capecitabine

Trial Locations (10)

Unknown

Aurora

Columbus

Salta

Lyon

Toulouse

Villejuif

Lima

Moscow

Obninsk

Kiev

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00124527 - Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer | Biotech Hunter | Biotech Hunter